Citric acid

Inventor of the Year Awarded to Developer of Phexxi®

Retrieved on: 
Monday, September 19, 2022
Securities Exchange Act of 1934, Therapy, Health, Infection, Sex, Chlamydia, COVID-19, Woman, FDA, Gonorrhea, Company, Private Securities Litigation Reform Act, Pregnancy, Reproductive health, STI, CDC, Annual report, Lactic acid, SAN, Citric acid, SEC, UIC, Birth control

SAN DIEGO, Sept. 19, 2022 /PRNewswire/ -- Evofem Biosciences (OTCPK: EVFM) is pleased to congratulate University of Illinois Chicago (UIC) Professor Emeritus Donald Waller, Ph.D., on his recognition as Inventor of the Year for his role in developing novel therapeutics for the improvement of women's health, including Phexxi® (lactic acid, citric acid, potassium bitartrate).

Key Points: 
  • "We started by looking at natural defenses both against pregnancy and against pathogens, such as gonorrhea and other STIs.
  • Phexxi, the first innovation in the contraceptive category in decades, was approved by the FDA in 2020 for prevention of pregnancy.
  • Since Phexxi's initial launch, over 100,000 women have been prescribed Phexxi by nearly 21,000 health care providers.
  • Positive study outcomes would enable regulatory submissions and potential approval for prevention of these sexually transmitted infections (STIs) in 2023.

Large Commercial Payer Adds Phexxi® to Formulary for Standard Plans Nationwide

Retrieved on: 
Friday, September 16, 2022
Securities Exchange Act of 1934, Sex, United States Department of Health and Human Services, Chlamydia, Human, Woman, FDA, Urinary tract infection, Treasury, Prescription, HIV, Company, Gonorrhea, Private Securities Litigation Reform Act, PBM, Birth control, Patient, Pregnancy, History, Bacterial vaginosis, Reproductive health, Human services, Male, Candidiasis, Annual report, New York State Department of Labor, Insurance, Lactic acid, SAN, Citric acid, SEC, Health, Health insurance, Healthcare, Lactic acid/citric acid/potassium bitartrate

SAN DIEGO, Sept. 16, 2022 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCPK: EVFM) today announced another new insurance win that gives millions of additional women access to Phexxi® (lactic acid, citric acid, potassium bitartrate) for the prevention of pregnancy.

Key Points: 
  • "Evofem's diligent efforts to expand access to Phexxi nationwide continue to pay off," said Saundra Pelletier, Chief Executive Officer of Evofem.
  • "We are thrilled that another highly respected national-level payer is now covering Phexxi, allowing women to fill their prescriptions immediately.
  • Evofem consistently engages with these payers to ensure they comply with these guidelines in covering Phexxi.
  • If you have a history of urinary tract problems that keep coming back, you should not use Phexxi.

Evofem Announces Successful Debt Restructuring

Retrieved on: 
Friday, September 16, 2022
Securities Exchange Act of 1934, Health, Sex, Chlamydia, Woman, FDA, Gonorrhea, Company, Private Securities Litigation Reform Act, Reproductive health, Annual report, Nasdaq, SAN, Security, Citric acid, SEC, Security (finance)

SAN DIEGO, Sept. 16, 2022 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCPK: EVFM) today announced the successful restructuring of its debt, providing forbearance from its debtholders related to all existing events of default.

Key Points: 
  • SAN DIEGO, Sept. 16, 2022 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCPK: EVFM)today announced the successful restructuring of its debt, providing forbearance from its debtholders related to all existing events of default.
  • "This debt restructuring removes the overhang created by the Nasdaq delisting last month while securing ongoing forbearance from current defaults," said Saundra Pelletier, Evofem's Chief Executive Officer.
  • In addition to the forbearance from all the Company's debtholders, other terms of the restructuring arrangements include:
    All holders of junior unsecured debt obligations have exchanged these obligations into rights to acquire Evofem's common stock.
  • In addition, the remaining unsecured creditor, Adjuvant Capital, exchanged 10% of its unsecured debt obligations into rights to acquire Evofem's common stock.

Suneva Medical Launches 30 mL PRP Gel Tubes of Amplifine, Allowing for More Variety and Efficiency in PRP Treatments

Retrieved on: 
Tuesday, September 13, 2022
Adoption, Risk, Efficiency, COVID-19, Sodium citrate, PIPE, Ageing, NYSE, FDA, Food, Sale, PRP, Blood, U.S. Securities and Exchange Commission, Name, Acquisition, Growth, Private Securities Litigation Reform Act, Partnership, Drawing, Centrifugation, Securities Act of 1933, Forward-looking statement, Patient, File, Regulation of tobacco by the U.S. Food and Drug Administration, Ownership, Standard of care, Use, Solution, CA, SPAC, Failure, NYSE American, Form, SAN, Citric acid, Prospectus, SEC, Proxy, Health, Multimedia, Regenerative medicine, View, Medical imaging, Risk management, Security (finance)

The 30 mL PRP tubes received a 510(k) clearance by the U.S. Food and Drug Administration (FDA) earlier this year.

Key Points: 
  • The 30 mL PRP tubes received a 510(k) clearance by the U.S. Food and Drug Administration (FDA) earlier this year.
  • The availability of the Amplifine 30mL PRP gel tube directly addresses the growing demand from practices and their patients to capture a higher volume of PRP for various clinical applications.
  • Amplifine PRP Gel Tube is designed to be used for the safe and rapid preparation of autologous platelet-rich plasma (PRP) from a small sample of peripheral blood at the patient point-of-care.
  • The Amplifine gel tube must be processed via centrifuge at a designated speed and length of time following blood draw.

Gelesis to Participate in the Jefferies Virtual Fitness & Wellness Summit

Retrieved on: 
Thursday, September 8, 2022
Fitness & Nutrition, Health, Other Health, Functional constipation, COVID-19, Security (finance), Citric acid, Food, Flatulence, Diarrhea, Pain scale, BMI, NYSE, Gel, Obesity, Perception, NAFLD, Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., Exercise, Abdomen, Allergy, Cellulose, XXV, 100,000, Incidence, Forward-looking statement, GLS, Diet, U.S. Securities and Exchange Commission, Defecation, New, Absorption, Body mass index, Patient, Use, Social media, FDA, Company, NASH, Twitter, Human, Type 2 diabetes, Failure, Chief commercial officer, Risk, Webcast, Non-alcoholic fatty liver disease, Intellectual property, Annual report, Gelatin, Growth, Industry, Social conditioning, Nature, Dietary supplement, Risk management, Gelesis, Hydrogel

Gelesis Holdings Inc. (NYSE: GLS) (Gelesis or the Company), the maker of Plenity for weight management, today announced that Yishai Zohar, Founder and Chief Executive Officer, Elliot Maltz, Chief Financial Officer, and David Pass, Chief Operating and Commercial Officer, will participate in the Jefferies Virtual Fitness & Wellness Summit on Monday, September 12, 2022.

Key Points: 
  • Gelesis Holdings Inc. (NYSE: GLS) (Gelesis or the Company), the maker of Plenity for weight management, today announced that Yishai Zohar, Founder and Chief Executive Officer, Elliot Maltz, Chief Financial Officer, and David Pass, Chief Operating and Commercial Officer, will participate in the Jefferies Virtual Fitness & Wellness Summit on Monday, September 12, 2022.
  • The live webcast can be accessed on the Events & Presentations section of the Gelesis Investor Relations website at https://ir.gelesis.com/ .
  • Gelesis Holdings Inc. (NYSE: GLS) (Gelesis) is a consumer-centered biotherapeutics company and the maker of Plenity, which is inspired by nature and FDA cleared to aid in weight management.
  • Gelesis gives no assurance that any expectations set forth in this press release will be achieved.

Gelesis to Participate in Fireside Chat with IPO Edge Today at 2:00 PM ET

Retrieved on: 
Wednesday, August 17, 2022
Alternative Medicine, FDA, Health, General Health, Pharmaceutical, Biotechnology, FDA, Allergy, Social conditioning, Intellectual property, U.S. Securities and Exchange Commission, Defecation, Exercise, Risk, Abdomen, Diet, Obesity, Industry, XXV, NYSE, Human, Forward-looking statement, 100,000, GLS, Failure, Growth, Incidence, Absorption, Security (finance), Annual report, Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., Perception, New, Pain scale, Chief commercial officer, Gel, Patient, NASH, Gelatin, COVID-19, Company, Type 2 diabetes, Twitter, Non-alcoholic fatty liver disease, Cellulose, Food, Use, NAFLD, Citric acid, Nature, Functional constipation, Social media, Webcast, Flatulence, Body mass index, IPO, Diarrhea, BMI, Dietary supplement, Risk management, Hydrogel, Gelesis

Gelesis Holdings Inc. (NYSE: GLS) (Gelesis or the Company) the maker of Plenity for weight management, today announced that the Company is participating in a fireside chat with IPO Edge today at 2:00 PM ET.

Key Points: 
  • Gelesis Holdings Inc. (NYSE: GLS) (Gelesis or the Company) the maker of Plenity for weight management, today announced that the Company is participating in a fireside chat with IPO Edge today at 2:00 PM ET.
  • Gelesis Holdings Inc. (NYSE: GLS) (Gelesis) is a consumer-centered biotherapeutics company and the maker of Plenity, which is inspired by nature and FDA cleared to aid in weight management.
  • Our first-of-their-kind non-systemic superabsorbent hydrogels are made entirely from naturally derived building blocks.
  • Gelesis gives no assurance that any expectations set forth in this press release will be achieved.

Evofem Biosciences to Host Investor Call on Thursday, August 11, 2022

Retrieved on: 
Thursday, August 11, 2022
FDA, Company, Woman, Webcast, Reproductive health, Gonorrhea, Software, Citric acid, Chlamydia, Sex

SAN DIEGO, Aug. 10, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (EVFM) will hold an investor call as follows:

Key Points: 
  • If participating by phone, please dial in approximately 15 minutes prior to the start of the call.
  • Evofem Biosciences, Inc., (EVFM) is developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from chlamydia and gonorrhea.
  • The Company's first FDA-approved product,Phexxi(lactic acid, citric acid and potassium bitartrate), is ahormone-free, on-demand prescription contraceptive vaginal gel.
  • It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex.

Gelesis to Report Second Quarter 2022 Financial Results on August 15, 2022

Retrieved on: 
Thursday, August 4, 2022
Alternative Medicine, General Health, Pharmaceutical, Health, FDA, Allergy, Liver, BMI, Defecation, Exercise, Risk, Abdomen, Diet, Obesity, Forward-looking statement, Human, NYSE, Failure, GLS, Growth, SEC, COVID, COVID 19, Incidence, Absorption, Xi, Environment, New, Pain scale, Gel, Patient, NASH, Gelatin, Use, Company, Type 2 diabetes, Twitter, Non-alcoholic fatty liver disease, Cellulose, Food, NAFLD, Citric acid, 100,000, Nature, Functional constipation, Webcast, Flatulence, Body mass index, Diarrhea, Ix, Adoption, Dietary supplement, Risk management, Nitenpyram, Hydrogel, Gelesis

Gelesis Holdings, Inc. (NYSE:GLS) (Gelesis or the Company), the maker of Plenity for weight management, today announced that the Company will report financial results for the Second Quarter ended June 30, 2022, on August 15, 2022 prior to the market open.

Key Points: 
  • Gelesis Holdings, Inc. (NYSE:GLS) (Gelesis or the Company), the maker of Plenity for weight management, today announced that the Company will report financial results for the Second Quarter ended June 30, 2022, on August 15, 2022 prior to the market open.
  • The live call can be accessed via webcast on the Events & Presentations section of the Gelesis Investor Relations website at https://ir.gelesis.com/ .
  • Gelesis Holdings Inc. (NYSE: GLS) (Gelesis) is a consumer-centered biotherapeutics company and the maker of Plenity, which is inspired by nature and FDA cleared to aid in weight management.
  • These filings address other important risks and uncertainties that could cause actual results and events to differ materially from those contained in the forward-looking statements.

Evofem Biosciences Strengthens Board of Directors

Retrieved on: 
Wednesday, August 3, 2022
Citric acid, Private Securities Litigation Reform Act, Harvard University, Annual report, Organization, Reproductive health, Birth, Partner, Board, Woman, SAN, Securities Exchange Act of 1934, Education, Company, Board of directors, FDA, Bill & Melinda Gates Foundation, Melinda Gates, Investment, Adjuvant, Health, Sex, Chlamydia, Gonorrhea, AB, SEC, History of science, Management, Pharmaceutical industry, Birth control

SAN DIEGO, Aug. 3, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced the appointment of Jenny Yip, a Managing Partner at life sciences investment fund Adjuvant Capital, to its Board of Directors.

Key Points: 
  • SAN DIEGO, Aug. 3, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced the appointment of Jenny Yip, a Managing Partner at life sciences investment fund Adjuvant Capital, to its Board of Directors.
  • The appointment of Ms. Yip as a director expands the Board from five to six independent directors.
  • Evofem invested in a large, undervalued market opportunity with the first innovation in contraception in decades," said Jenny Yip.
  • Evofem Biosciences, Inc., (Nasdaq: EVFM) is developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from chlamydia and gonorrhea.

Honest Beauty Expands Distribution with New In-store Presence at Ulta Beauty

Retrieved on: 
Tuesday, August 2, 2022
Cosmetics, Retail, Foam, CA, Breakout (video game), Beauty, Skin, Laboratory, Trust, The Honest Company, Citric acid, Trial of the century, Blemish, Ulta Beauty, Pigment, Malic, Salicylic acid, Partnership, Azelaic acid, Microalgae, Health, Collection, Apple, Safety, NASDAQ, Household, Sulfur, Company, Acne, PCA, Serum, Cosmetics, Beauty salon, Glycolic acid, Honesty, Nicotinamide

The brand also launched its new skincare line, the Honest Beauty Clearing Collection, with Ulta Beauty, both online and in-stores.

Key Points: 
  • The brand also launched its new skincare line, the Honest Beauty Clearing Collection, with Ulta Beauty, both online and in-stores.
  • We see a huge opportunity to meet the needs of the clean and conscious beauty consumer with Ulta Beauty, said Jessica Alba, founder, The Honest Company.
  • The Ulta Beauty guest truly knows beauty inside and out, and we are thrilled to expand our partnership to bring our best in class products to guests in-stores nationwide.
  • We are pleased to welcome Honest Beauty to our unparalleled assortment, especially as our guests continue to seek out clean beauty products more fervently than ever before, said Monica Arnaudo, chief merchandising officer, Ulta Beauty.